AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Trafficking protein particle complex subunit 14

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8WVR3

UPID:

TPC14_HUMAN

Alternative names:

Microtubule-associated protein 11

Alternative UPACC:

Q8WVR3; A4D2A9; D6W5U4; Q9BQJ1; Q9BUB6; Q9NV47

Background:

Trafficking protein particle complex subunit 14, also known as Microtubule-associated protein 11, plays a pivotal role in cellular processes. It is a specific subunit of the TRAPP II complex, involved in late Golgi trafficking, membrane tethering, and has GEF activity toward RAB1A. Additionally, it is crucial for preciliary vesicle trafficking during ciliogenesis and modulates YAP1 activity, a transcriptional regulator.

Therapeutic significance:

Linked to Microcephaly 25, primary, autosomal recessive, this protein's dysfunction manifests in severe neurological conditions. Understanding the role of Trafficking protein particle complex subunit 14 could open doors to potential therapeutic strategies for treating not only microcephaly but also related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.